METHODS OF TREATING ERYTHROPOIETIC PROTOPORPHYRIA, X-LINKED PROTOPORPHYRIA, OR CONGENITAL ERYTHROPOIETIC PORPHYRIA WITH GLYCINE TRANSPORT INHIBITORS
The present embodiments are directed to methods of using glycine transporter inhibitors, such as GlyT1 inhibitors, or pharmaceutically acceptable salts, solvates or prodrugs thereof, or pharmaceutical compositions thereof, for preventing or treating erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLPP), and/or congenital erythropoietic porphyria (CEP), and related syndromes thereof..
Medienart: |
Patent |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Europäisches Patentamt - (2024) vom: 03. Apr. Zur Gesamtaufnahme - year:2024 |
---|
Sprache: |
Englisch |
---|
Beteiligte Personen: |
MACDONALD BRIAN RICHARD [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
Themen: |
Sonstige Themen: |
---|
Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2024-04-03, Last update posted on www.tib.eu: 2024-04-16, Last updated: 2024-04-19 |
---|
Patentnummer: |
EP4087570 |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
EPA000109169 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | EPA000109169 | ||
003 | DE-627 | ||
005 | 20240419123107.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240315s2024 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)EPA000109169 | ||
035 | |a (EPA)EP4087570 | ||
035 | |a (EPA)76788330 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 0 | |a MACDONALD BRIAN RICHARD |e verfasserin |4 aut | |
245 | 1 | 0 | |a METHODS OF TREATING ERYTHROPOIETIC PROTOPORPHYRIA, X-LINKED PROTOPORPHYRIA, OR CONGENITAL ERYTHROPOIETIC PORPHYRIA WITH GLYCINE TRANSPORT INHIBITORS |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Source: www.epo.org (no modifications made), First posted: 2024-04-03, Last update posted on www.tib.eu: 2024-04-16, Last updated: 2024-04-19 | ||
520 | |a The present embodiments are directed to methods of using glycine transporter inhibitors, such as GlyT1 inhibitors, or pharmaceutically acceptable salts, solvates or prodrugs thereof, or pharmaceutical compositions thereof, for preventing or treating erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLPP), and/or congenital erythropoietic porphyria (CEP), and related syndromes thereof. | ||
650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
650 | 4 | |a che | |
650 | 4 | |a 615 | |
700 | 0 | |a BECONI MARIA GABRIELA |e verfasserin |4 aut | |
700 | 0 | |a HONG VU |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2024) vom: 03. Apr. |
773 | 1 | 8 | |g year:2024 |g day:03 |g month:04 |
856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/76788330/publication/EP4087570A1?q=EP4087570 |x 0 |z kostenfrei |3 Volltext |
912 | |a GBV_EPA | ||
951 | |a AR | ||
952 | |j 2024 |b 03 |c 04 |